Purpose: To evaluate the safety, efficacy, predictability, and stability of conductive keratoplasty (CK) for the treatment of hyperopic astigmatism.
Setting: University of Crete Medical School, Vardinoyannion Eye Institute of Crete, Heraklion, Greece.
Methods: In this prospective nonrandomized noncontrolled single-center study, 47 eyes of 34 patients (15 women and 19 men) were treated for hyperopic astigmatism (up to + 3.50 diopters [D]) with a Refractec ViewPoint CK system and followed for 24 months +/- 0.6 (SD). The treatment consisted of 4 to 36 spots applied to the periphery of the cornea. Mean age was 48.5 years +/- 9.7 years, range 25 to 68 years. All the treated eyes were analyzed for safety, efficacy, predictability, and stability.
Results: The mean patient age was 48.5 +/- 9.7 years (range 25 to 68 years). Preoperatively, the mean manifest refraction spherical equivalent (MRSE) was +2.11 +/- 0.88 D (range -0.50 to + 4.13 D); at 12 months, it was -0.52 +/- 0.73 D and at 24 months, -0.50 +/- 0.77 D. At 24 months, the mean MRSE was within +/-0.50 D in 61% of eyes, within +/-1.00 D in 83%, and within +/-2.00 D in all eyes. At 24 months, the uncorrected visual acuity was 20/20 or better in 37% of eyes and 20/40 or better in 97%. By the end of the follow-up period, no eye had lost > or =2 Snellen lines or had an induced cylinder > or =1.50 D.
Conclusions: Conductive keratoplasty for low hyperopic astigmatism was a safe, effective, and stable procedure. Nomogram adjustments and careful patient selection should contribute to higher levels of predictability when treating hyperopic astigmatism.